Analysis of the autoantibody repertoire in Burkitt's lymphoma patients: Frequent response against the transcription factor ATF-2

Cancer Immunology, Immunotherapy

Volumn 53, Issue 12, 2004, Pages 1119-1126

  Kersten, Christian ^a   Delabie, Jan ^a   Gaudernack, Gustav ^a   Smeland, Erlend B ^a   Fosså, Alexander ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

ATF 2; Burkitt's lymphoma; Non Hodgkin's lymphoma; SEREX; Tumour immunology; Tumour associated antigen

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; AUTOANTIBODY; COMPLEMENTARY DNA; RECOMBINANT PROTEIN; TRANSCRIPTION FACTOR; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; B CELL LYMPHOMA; BURKITT LYMPHOMA; CONTROLLED STUDY; DNA LIBRARY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLICULAR LYMPHOMA; GENE IDENTIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MOLECULAR CLONING; NONHODGKIN LYMPHOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; VALIDATION PROCESS; WESTERN BLOTTING;

ACTIVATING TRANSCRIPTION FACTOR 2; AUTOANTIBODIES; BURKITT LYMPHOMA; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; GENE LIBRARY; HUMANS; IMMUNOHISTOCHEMISTRY; RECOMBINANT PROTEINS; RNA, MESSENGER; TRANSCRIPTION FACTORS;

EID: 8644245793     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-004-0558-0     Document Type: Article

References (54)

1. Adamson AL, Darr D, Holley-Guthrie E, Johnson RA, Mauser A, Swenson J, Kenney S (2000) Epstein-Barr virus immediate-early proteins BZLF1 and BRLF1 activate the ATF2 transcription factor by increasing the levels of phosphorylated p38 and c-Jun N-terminal kinases. J Virol 74:1224-1233
2. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J Jr, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Staudt LM (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503-511
3. Andersen MH, Bonfill JE, Neisig A, Arsequell G, Sondergaard I, Valencia G, Neefjes J, Zeuthen J, Elliott T, Haurum JS (1999) Phosphorylated peptides can be transported by TAP molecules, presented by class 1 MHC molecules, and recognized by phosphopeptide-specific CTL. J Immunol 163:3812-3818
4. Bellan C, Lazzi S, De Falco G, Nyongo A, Giordano A, Leoncini L (2003) Burkitt's lymphoma: new insights into molecular pathogenesis. J Clin Pathol 56:188-192
5. Campbell P, Marcus R (2003) Monoclonal antibody therapy for lymphoma. Blood Rev 17:143-152
6. Chen G, Gharib TG, Wang H, Huang CC, Kuick R, Thomas DG, Shedden KA, Misek DE, Taylor JM, Giordano TJ, Kardia SL, Iannettoni MD, Yee J, Hogg PJ, Orringer MB, Hanash SM, Beer DG (2003) Protein profiles associated with survival in lung adenocarcinoma. Proc Natl Acad Sci U S A 100:13537-13542
7. Chiang PK, Gordon RK, Tal J, Zeng GC, Doctor BP, Pardhasaradhi K, McCann PP (1996) S-Adenosylmethionine and methylation. FASEB J 10:471-480
8. De Cesare D, Fimia GM, Sassone-Corsi P (1999) Signaling routes to CREM and CREB: plasticity in transcriptional activation. Trends Biochem Sci 24:281-285
9. De Clercq E (2002) Strategies in the design of antiviral drugs. Nat Rev Drug Discov 1:13-25
10. Duyndam MC, van Dam H, Smits PH, Verlaan M, van der Eb AJ, Zantema A (1999) The N-terminal transactivation domain of ATF2 is a target for the co-operative activation of the c-jun promoter by p300 and 12S E1A. Oncogene 18:2311-2321
11. Ehlken H, Schadendorf D, Eichmuller S (2004) Humoral immune response against melanoma antigens induced by vaccination with cytokine gene-modified autologous tumor cells. Int J Cancer 108:307-313
12. Eichmuller S, Usener D, Dummer R, Stein A, Thiel D, Schadendorf D (2001) Serological detection of cutaneous T-cell lymphoma-associated antigens. Proc Natl Acad Sci U S A 98:629-634
13. Eliopoulos AG, Gallagher NJ, Blake SM, Dawson CW, Young LS (1999) Activation of the p38 mitogen-activated protein kinase pathway by Epstein-Barr virus-encoded latent membrane protein 1 coregulates interleukin-6 and interleukin-8 production. J Biol Chem 274:16085-16096
14. Fossa A, Alsoe L, Crameri R, Funderud S, Gaudernack G, Smeland EB (2004) Serological cloning of cancer/testis antigens expressed in prostate cancer using cDNA phage surface display. Cancer Immunol Immunother 53:431-438
15. Fossa A, Siebert R, Aasheim HC, Maelandsmo GM, Berner A, Fossa SD, Paus E, Smeland EB, Gaudernack G (2000) Identification of nucleolar protein No55 as a tumour-associated autoantigen in patients with prostate cancer. Br J Cancer 83:743-749
16. Fuchs SY, Ronai Z (1999) Ubiquitination and degradation of ATF2 are dimerization dependent. Mol Cell Biol 19:3289-3298
17. Gensler TJ, Hottelet M, Zhang C, Schlossman S, Anderson P, Utz PJ (2001) Monoclonal antibodies derived from BALB/c mice immunized with apoptotic Jurkat T cells recognize known autoantigens. J Autoimmun 16:59-69
18. Godfried MB, Veenstra M, Sluis P, Boon K, Asperen R, Hermus MC, Schaik BD, Voute TP, Schwab M, Versteeg R, Caron HN (2002) The N-myc and c-myc downstream pathways include the chromosome 17q genes nm23-H1 and nm23-H2. Oncogene 21:2097-2101
19. Gupta S, Campbell D, Derijard B, Davis RJ (1995) Transcription factor ATF2 regulation by the JNK signal transduction pathway. Science 20(267):389-393
20. Hansen MH, Nielsen H, Ditzel HJ (2001) The tumor-infiltrating B cell response in medullary breast cancer is oligoclonal and directed against the autoantigen actin exposed on the surface of apoptotic cancer cells. Proc Natl Acad Sci U S A 98:12659-12664
21. Hartmann TB, Thiel D, Dummer R, Schadendorf D, Eichmuller S (2004) SEREX identification of new tumour-associated antigens in cutaneous T-cell lymphoma. Br J Dermatol 150:252-258
22. Hecht JL, Aster JC (2000) Molecular biology of Burkitt's lymphoma. J Clin Oncol 18:3707-3721
23. Huang S, Preuss KD, Xie X, Regitz E, Pfreundschuh M (2002) Analysis of the antibody repertoire of lymphoma patients. Cancer Immunol Immunother 51:655-662
24. Ji L, Arcinas M, Boxer LM (1995) The transcription factor, Nm23H2, binds to and activates the translocated c-myc allele in Burkitt's lymphoma. J Biol Chem 270:13392-13398
25. Kastrup IB, Andersen MH, Elliott T, Haurum JS (2001) MHC-restricted T cell responses against posttranslationally modified peptide antigens. Adv Immunol 78:267-289
26. Kim HS, Jeong SY, Lee JH, Kim BE, Kim JW, Jeong SW, Kim IK (2000) Induction of apoptosis in human leukemia cells by 3-deazaadenosine is mediated by caspase-3-like activity. Exp Mol Med 32:197-203
27. Klein G, Dombos L, Gothoskar B (1972) Sensitivity of Epstein-Barr virus (EBV) producer and non-producer human lymphoblastoid cell lines to superinfection with EB-virus. Int J Cancer 10:44-57
28. Krackhardt AM, Witzens M, Harig S, Hodi FS, Zauls AJ, Chessia M, Barrett P, Gribben JG (2002) Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX. Blood 100:2123-2131
29. Lehmeier T, Raker V, Hermann H, Luhrmann R (1994) cDNA cloning of the Sm proteins D2 and D3 from human small nuclear ribonucleoproteins: evidence for a direct D1-D2 interaction. Proc Natl Acad Sci U S A 91:12317-12321
30. Li G, Miles A, Line A, Rees RC (2004) Identification of tumour antigens by serological analysis of cDNA expression cloning. Cancer Immunol Immunother 53:139-143
31. Line A, Slucka Z, Stengrevics A, Silina K, Li G, Rees RC (2002) Characterisation of tumour-associated antigens in colon cancer. Cancer Immunol Immunother 51:574-582
32. Martinez JA, Prevot S, Nordlinger B, Nguyen TM, Lacarriere Y, Munier A, Lascu I, Vaillant JC, Capeau J, Lacombe ML (1995) Overexpression of nm23-H1 and nm23-H2 genes in colorectal carcinomas and loss of nm23-H1 expression in advanced tumour stages. Gut 37:712-720
33. Mathas S, Hinz M, Anagnostopoulos I, Krappmann D, Lietz A, Jundt F, Bommert K, Mechta-Grigoriou F, Stein H, Dorken B, Scheidereit C (2002) Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B. EMBO J 21:4104-4113
34. Miethe J, Schwartz C, Wottrich K, Wenning D, Klempnauer KH (2001) Crosstalk between Myc and activating transcription factor 2 (ATF2): Myc prolongs the half-life and induces phosphorylation of ATF2. Oncogene 20:8116-8124
35. Montgomerie JZ, Gracy RW, Holshuh HJ, Keyser AJ, Bennett CJ, Schick DG (1997) The 28 K protein in urinary bladder, squamous metaplasia and urine is triosephosphate isomerase. Clin Biochem 30:613-618
36. Nemecek ER, Matthews DC (2002) Antibody-based therapy of human leukemia. Curr Opin Hematol 9:316-321
37. Nishikawa H, Tanida K, Ikeda H, Sakakura M, Miyahara Y, Aota T, Mukai K, Watanabe M, Kuribayashi K, Old LJ, Shiku H (2001) Role of SEREX-defined immunogenic wild-type cellular molecules in the development of tumor-specific immunity. Proc Natl Acad Sci U S A 98:14571-14576
38. Okabe M, Matsushima S, Morioka M, Kobayashi M, Abe S, Sakurada K, Kakinuma M, Miyazaki T (1987) Establishment and characterization of a cell line, TOM-1, derived from a patient with Philadelphia chromosome-positive acute lymphocytic leukemia. Blood 69:990-998
39. Ouwens DM, de Ruiter ND, van der Zon GC, Carter AP, Scheuten J, van der Burgt C, Kooistra K, Bos JL, Maassen JA, van Dam H (2002) Growth factors can activate ATF2 via a two-step mechanism: phosphorylation of Thr71 through the Ras-MEK-ERK pathway and of Thr69 through Ra1GDS-Src-p38. EMBO J 21:3782-3793
40. Pfreundschuh M (2000) Exploitation of the B cell repertoire for the identification of human tumor antigens. Cancer Chemother Pharmacol 46 (3-7):S3-S7
41. Pieper R, Christian RE, Gonzales MI, Nishimura MI, Gupta G, Settlage RE, Shabanowitz J, Rosenberg SA, Hunt DF, Topalian SL (1999) Biochemical identification of a mutated human melanoma antigen recognized by CD4(+) T cells. J Exp Med 189:757-766
42. Postel EH, Berberich SJ, Flint SJ, Ferrone CA (1993) Human c-myc transcription factor PuF identified as nm23-H2 nucleoside diphosphate kinase, a candidate suppressor of tumor metastasis. Science 261:478-480
43. Preuss KD, Zwick C, Bormann C, Neumann F, Pfreundschuh M (2002) Analysis of the B-cell repertoire against antigens expressed by human neoplasms. Immunol Rev 188:43-50
44. Sahin U, Tureci O, Schmitt H, Cochlovius B, Johannes T, Schmits R, Stenner F, Luo G, Schobert I, Pfreundschuh M (1995) Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci U S A 92:11810-11813
45. Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT (2002) Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 188:22-32
46. Schaade L, Kleines M, Krone B, Hausding M, Walter R, Ritter K (2000) Enhanced transcription of the s-adenosylhomocysteine hydrolase gene precedes Epstein-Barr virus lytic gene activation in ganglioside-stimulated lymphoma cells. Med Microbiol Immunol (Berl) 189:13-18
47. Schmits R, Cochlovius B, Treitz G, Regitz E, Ketter R, Preuss KD, Romeike BF, Pfreundschuh M (2002) Analysis of the antibody repertoire of astrocytoma patients against antigens expressed by gliomas. Int J Cancer 98:73-77
48. Schuldiner O, Shor S, Benvenisty N (2002) A computerized database-scan to identify c-MYC targets. Gene 292:91-99
49. Shaulian E, Karin M (2002) AP-1 as a regulator of cell life and death. Nat Cell Biol 4:E131-E136
50. Sillekens PT, Beijer RP, Habets WJ, van Verooij WJ (1989) Molecular cloning of the cDNA for the human U2 snRNA-specific A' protein. Nucleic Acids Res 17:1893-1906
51. Stager S, Alexander J, Kirby AC, Botto M, Rooijen NV, Smith DF, Brombacher F, Kaye PM (2003) Natural antibodies and complement are endogenous adjuvants for vaccine-induced CD8(+) T-cell responses. Nat Med 9:1287-1292
52. Su AI, Cooke MP, Ching KA, Hakak Y, Walker JR, Wiltshire T, Orth AP, Vega RG, Sapinoso LM, Moqrich A, Patapoutian A, Hampton GM, Schultz PG, Hogenesch JB (2002) Large-scale analysis of the human and mouse transcriptomes. Proc Natl Acad Sci U S A 99:4465-4470
53. Van Dam H, Castellazzi M (2001) Distinct roles of Jun: Fos and Jun: ATF dimers in oncogenesis. Oncogene 20:2453-2464
54. Xu X, Heidenreich O, Kitajima I, McGuire K, Li Q, Su B, Nerenberg M (1996) Constitutively activated JNK is associated with HTLV-1 mediated tumorigenesis. Oncogene 13:135-142